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ABSTRACT
Objective: This study aimed to investigate the efficacy of curcumin (CMN) and nanocurcumin (NC) at preventing cisplatin (CDPP)-induced 
nephrotoxicity.
Methods: Two membrane transporters, copper transporter 1 (CTR1) and organic cation transporter 2 (OCT2), have been identified involved in active 
accumulation of CDPP into renal tubular cells. We analyzed OCT2 transcription levels in rat kidney tissue and determined whether renoprotective 
mechanism of CMN involves CTR1. Rats were randomly divided into five groups: (1) Control, (2) CDPP (7 mg/kg as single dose (i.p.), (3) CDPP+CMN 
(7 mg/kg CDPP as a single dose, i.p.+100 mg/kg/day of CMN), (4) CDPP+50 mg NC (7 mg/kg CDPP as single dose, i.p.+50 mg/kg/day NC), and 
(5) CDPP+100 mg NC (7 mg/kg CDPP as single dose, i.p.+100 mg/kg/day NC). Quantitative reverse transcription-polymerase chain reaction was 
performed to calculate relative expression of CTR1 and OCT2 genes in rat kidney.
Results: Expression of CTR1 was unassociated with administration of CMN or NC, indicating CTR1 is uninvolved in renoprotective mechanism of CMN. 
The administration of 100 mg/kg/day NC increased expression of OCT2; this increase was higher compared with normal expression levels. This may 
be due to another regulatory mechanism from the CMN itself.
Conclusion: NC has a better renoprotective effect compared with curcumin, suggested by the increased OCT2 expression on its administration in 
CDPP-treated rats.
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INTRODUCTION
Cisplatin (CDPP) (cis-diamminedichloroplatinum [II]) is a potent 
antineoplastic drug used for the treatment of solid tumors. It has been 
extensively used for a wide variety of neoplasms including those of the 
lung, head and neck, breast, ovary, blood, brain, kidney, and testes [1]. 
However, the dose of CDPP is ultimately limited due to its adverse 
effects, which reduces its overall effectiveness. The clinical usefulness 
of this drug is limited due to the presence of platinum in the kidney and 
liver [2]. The disproportionate accumulation of CDPP in kidney tissue 
contributes to CDPP-induced nephrotoxicity [3]. It clinically manifests as 
a lower glomerular filtration rate, higher serum creatinine, and reduced 
serum magnesium and potassium levels occurring in about one-third of 
patients undergoing CDPP treatment [4]. This adverse effect typically 
evolves slowly and predictably after initial and repeated exposure [5].
The major pathological basis of CDPP nephrotoxicity is renal tubular 
cell death on exposure [4]. CDPP is taken up by tubular cells to be 
eliminated from the body. In recent years, it has become evident that 
the cellular uptake of CDPP is mediated, at least in part, by specific 
transport proteins. Transport proteins that have been reported to be 
associated with CDPP uptake into renal tubular cells and consequent 
nephrotoxicity include copper transporter 1 (CTR1) and organic cation 
transporter 2 (OCT2) [6-8].
Curcumin (CMN) is an active compound extracted from the rhizome of 
the plant Curcuma longa and has been reported to have renoprotective 
effects [9]. CMN has been known for its numerous pharmacological 
activities including antioxidant, anti-inflammatory and antimicrobial 
properties, and chemopreventive and chemotherapeutic activity [10]. In 
addition, CMN appears to reverse the effects of CDPP, which includes a 
decrease in the expression of OCT2. This decreases in OCT2 expression in 
response to CDPP is believed to be a natural renoprotective mechanism 
of the kidney to prevent further toxicity from CDPP, the uptake of which 
is mediated by this transporter. Hence, a decrease in the reduction level 
of OCT2 in the kidneys of animals treated with CDPP and CMN indicates 
less renal damage compared with kidneys treated with CDPP alone. This 
is consistent with histopathological findings of CDPP-induced changes 
(particularly interstitial edema, tubular vacuolation, necrosis, and 
atrophy). These histopathological changes are found significantly less 
in CMN+CDPP-treated groups. Various studies have also demonstrated 
that CMN is extremely safe even at very high doses [11-16].
Unfortunately, pharmacokinetic studies of CMN have revealed poor 
absorption, rapid metabolism, and elimination, resulting in poor 
bioavailability [17]. Another factor that contributes to the poor 
bioavailability of CMN is its low solubility in water, and soluble CMN 
molecules are unstable at physiological pH [18]. Efforts have been made 
to enhance the bioavailability of CMN including the use of adjuvants, 
liposomes, micelles, phospholipid complexes, and nanoparticles [17]. In 
this study, nanocurcumin (NC) was used to increase the bioavailability of 
CMN. With enhanced bioavailability, the improved renoprotective abilities 
of CMN are expected to better attenuate CDPP-induced nephrotoxicity. 
Therefore, the aim of this study was to investigate the differences between 
the effects of CMN and NC in preventing CDPP-induced nephrotoxicity. To 
this end, we analyzed OCT2 transcription levels in rat kidney tissue and 
examined the effects of CMN and NC on CTR1.
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METHODS
Ethics statement and experimental animals
Male Sprague-Dawley rats weighing 150–300 g were obtained from 
LITBANGKES (Jakarta, Indonesia). Rats were acclimatized for a 
week before the study. Rats were housed under standard laboratory 
conditions at a temperature of 22±2°C with a relative humidity of 
65±10% and were provided a standard pellet rodent diet and water 
ad libitum during the study. Experiments were approved by the 
Institutional Animal Ethics Committee of Universitas Indonesia.
Drugs and chemicals
Cisplatin (CDPP) was purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and was suspended in normal saline (0.9% NaCl). CMN and NC were 
purchased from PT Plamed Green Science Limited (China). Molecular 
size analysis was performed, and it was determined that the average 
molecular size of NC was 240.7 nm (standard deviation [SD]=53.5), 
whereas the average molecular size of CMN was 331.7 nm (SD=91.0). 
CMN and NC were suspended in 0.5% carboxymethylcellulose (CMC).
Experimental design
A total of 23 rats were divided into five groups at random: (1) Control 
rats (n=4), which received daily administrations of 0.5% CMC-Na orally 
for 9 consecutive days and a single intraperitoneal (i.p.) injection of 
0.9% normal saline on the 7th day; (2) the CDPP group (n=4), which 
received daily administrations of 0.5% CMC-Na orally for 9 consecutive 
days and a single i.p. injection of CDPP (7 mg/kg dissolved in 0.9% 
normal saline) on the 7th day; (3) the CDPP+CMN group (n=5), which 
received daily administrations of CMN (100 mg/kg/day dispersed in 
0.5% CMC-Na) orally for 9 consecutive days and a single i.p. injection of 
CDPP (7 mg/kg dissolved in 0.9% normal saline) on the 7th day; (4) the 
CDPP+50 mg NC group (n=5), which received daily administrations of 
NC (50 mg/kg/day dispersed in 0.5% CMC-Na) orally for 9 consecutive 
days and a single i.p. injection of CDPP (7 mg/kg dissolved in 0.9% 
normal saline) on the 7th day; and (5) the CDPP + 100 mg NC group 
(n=5), which received daily administrations of NC (100 mg/kg/day 
dispersed in 0.5% CMC-Na) orally for 9 consecutive days and a single 
i.p. injection of CDPP (7 mg/kg dissolved in 0.9% normal saline) on the 
7th day. Rats were weighed regularly during the experiment. 24 h after 
CDPP injection, all rats were placed individually in metabolic cages for 
urine collection. At the end of the experiment (i.e., on the 10th day), rats 
were anesthetized with ether and sacrificed by cervical decapitation. 
Kidneys were isolated and stored at −80°C for gene expression analysis 
by quantitative reverse transcription-polymerase chain reaction (qRT-
PCR) and electrophoresis.
Data collection and analysis
Kidney tissue was homogenized with ice-cold saline (0.9% sodium 
chloride) using a rotor-stator homogenizer. The mixture was 
centrifuged for 10 min at 3000×g at 4°C. The supernatant was then 
collected, and RNA was isolated using the Tripure Isolation Reagent. 
Next, cDNA was synthesized using a Transcriptor First Strand cDNA 
Synthesis Kit (Roche) before two-step qRT-PCR was performed. The 
purity and concentration of the cDNA in the samples was assessed 
using a Nanodrop 2000 spectrophotometer. qRT-PCR for CTR1, 
OCT2, as well as beta-actin as a reference gene was then carried 
out. The relative expression of CTR1 and OCT2 was calculated using 
the Livak method by comparing the quantitation cycle values of the 
treated group with those of the control group. Analysis of the data 
was carried out using the Statistical Package for the Social Sciences 
software, version 20. After qRT-PCR, visualization of gene expression 
was performed by electrophoresis (Bio-Rad). Gels were 2% agarose 
immersed in 2% tris-acetate-ethylenediaminetetraacetic acid buffer. 
Samples were mixed with SYBR Green loading dye and electrophoresed 
for 10 min at 220 V.
RESULTS
The results of qRT-PCR for CTR1 indicated no association between 
the administration of CMN and NC and respective gene expression as 
shown in Fig. 1. In the analysis, the median was used instead of the 
average due to the abnormal spread of the data.
The median of OCT2 qRT-PCR results showed an increased expression 
in rats treated with CDPP+100 mg NC compared with the other groups, 
although this finding was not significant (Fig. 2).
Statistical analysis showed no statistically significant result for either 
CTR1 or OCT2 (p>0.05). Electrophoresis of the CTR1 qRT-PCR product 
was inconclusive due to only a very slight difference between the 
expressions (Fig. 3).
Electrophoresis of the OCT2 qRT-PCR product showed an increased 
expression in the CDPP+100 mg NC group (Fig. 4, the two rightmost 
wells).
Fig. 1: Expression level of copper transporter 1
Fig. 2: Expression level of organic cation transporter 2
Fig. 3: Electrophoresis of copper transporter 1
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DISCUSSION
An important process mediating the cellular accumulation of CDPP 
inside renal tubular cells is transporter-mediated uptake [6]. Two 
identified membrane transporters involved in the active accumulation 
of CDPP into renal tubular cells are CTR1 and OCT2 [19]. However, 
no study has yet elucidated the effects of CDPP toward CTR1 gene 
expression or the effect of CMN toward CTR1 gene expression in CDPP-
induced nephrotoxicity. As for OCT2, several studies have elucidated that 
OCT2 expression is suppressed on CDPP treatment, which is presumed 
to be a natural renoprotective mechanism of the kidney to prevent 
further toxicity [20]. Therefore, CTR1 and OCT2 expression levels were 
used in this study to determine whether the renoprotective mechanism 
of CMN involves CTR1 and whether NC has better renoprotective effects 
compared with CMN.
Collectively, our research suggested no association between the 
administration of CMN or NC with CTR1 expression level. Thus, the 
renoprotective mechanism of CMN does not appear to involve CTR1. 
However, in accordance with previous studies, OCT2 gene expression 
was increased in the CDPP+100 mg/kg/day NC group. Although the 
expression was higher than normal levels, this indicates a better 
renoprotective effect of NC compared with CMN. These results are 
expected as the molecular size of NC would make it more readily 
dispersed in aqueous solutions, with subsequent better physical-
chemical properties compared with CMN. As for the overexpression, this 
may be caused by another regulatory mechanism from the CMN itself.
CONCLUSION
The administration of 100 mg/kg/day NC increased OCT2 expression 
in rats treated with CDPP; however, this increase was higher compared 
with normal expression levels. In contrast, CTR1 expression was not 
associated with the administration of CMN or NC; thus, it does not 
appear to be involved in the renoprotective mechanism of CMN.
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